Legend: 
= Applied Session,
= Theme Session,
= Presenter, Sheraton Seattle Hotel & Towers = “S”
Washington State Convention & Trade Center = “CC”, Grand Hyatt Seattle = “H”
|
|
|
|
|
472
|
Wed, 8/9/06, 2:00 PM - 3:50 PM
|
CC-2B
|
|
Osteoporosis, Contraceptive, and Vaccine Trials - Contributed - Papers
|
Biopharmaceutical Section, Biometrics Section, ENAR
|
|
Chair(s): Margaret Minkwitz, AstraZeneca Pharmaceuticals
|
|
2:05 PM
|
Quantitative Risk-Benefit Assessment in the Multiple Outcomes of Raloxifene Evaluation (MORE) Trial: an Application of the Global Benefit-Risk Assessment —  Messan G. Amewou-Atisso, Eli Lilly and Company; Yili Pritchett, Abbott Laboratories
|
|
2:20 PM
|
Quantifying the Effect of the Surrogate Marker by Information Gain — Yongming Qu, Eli Lilly and Company; Michael Case, Eli Lilly and Company
|
|
2:35 PM
|
Assessing Learning Effect and Nonrandom Dropout in a Contraceptive Device Trial — Pai-Lien Chen, Family Health International
|
|
2:50 PM
|
An Improved Exact Method for the Estimation and Testing of a Rate Ratio — William W. B. Wang, Merck Research Laboratories; Ivan Chan, Merck & Co., Inc.
|
|
3:05 PM
|
A Statistical Framework for Quantile Equivalence Clinical Trials with Application to Pharmacokinetic Studies That Bridge from HIV-Infected Adults to Children — Lixia Pei, Harvard University; Michael Hughes, Harvard University
|
|
3:20 PM
|
The Use of an Internal Unblinded Statistician with a Data-Monitoring Committee — David Radley, Merck & Co., Inc.; Gregory Golm, Merck & Co., Inc.
|
|
3:35 PM
|
Floor Discussion
|
| |
